

Effects of 22 novel *CYP2D6* variants found in Chinese population on the metabolism of dapoxetine

Ren-ai Xu^{1,*}Er-min Gu^{2,*}Quan Zhou²Lingjing Yuan²Xiaoxia Hu²Jianping Cai³Guoxin Hu^{1,2}

¹Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, ²Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, Wenzhou, ³The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, People's Republic of China

*These authors contributed equally to this work

Correspondence: Guoxin Hu
The First Affiliated Hospital of Wenzhou Medical University, University-Town, Wenzhou 32500, Zhejiang, People's Republic of China
Fax +86 577 8668 9983
Email hgx@wzmc.edu.cn

Jianping Cai
The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing 100730, People's Republic of China
Fax +86 10 6523 7929
Email caijp61@vip.sina.com

Background: *CYP2D6* is one of the most important members of the cytochrome P450 superfamily. Its genetic polymorphism significantly influences the efficacy and safety of some drugs, which might cause adverse effects and therapeutic failure.

Methods and results: The aim of this research was mainly to explore the catalytic activities of 22 newly reported *CYP2D6* isoforms (*2D6*87*, **88*, **89*, **90*, **91*, **92*, **93*, **94*, **95*, **96*, **97*, **98*, **R25Q*, *F164L*, *E215K*, *F219S*, *V327M*, *D336N*, *V342M*, *R344Q*, *R440C*, *R497C*) on dapoxetine in vitro. The research was designed with an appropriate incubation system in test tubes and carried out in the constant temperature water. Through detecting its two metabolites desmethyldapoxetine and dapoxetine-N-oxide, the available data were obtained to explain the influence of *CYP2D6* polymorphism on the substrate drug dapoxetine. As a result, the intrinsic clearance (V_{\max}/K_m) values of most variants were significantly altered when compared with the counterpart of *CYP2D6*1*, with most of these variants exhibiting either reduced V_{\max} and/or increased K_m values. For dapoxetine demethylation pathway (which produces desmethyldapoxetine), *2D6*89* and *E215K* exhibited no markedly decreased relative clearance of 92.81% and 97.70%, respectively. The relative clearance of rest 20 variants exhibited decrease in different levels, ranging from 20.44% to 90.90%. For the dapoxetine oxidation pathway (which produces dapoxetine-N-oxide), the relative clearance values of three variants, *2D6*90*, **94*, and *V342M*, exhibited no markedly increased relative clearance of 106.17%, 107.78%, and 109.98%, respectively; the rest 19 variants exhibited significantly decreased levels ranging from 27.56% to 84.64%. In addition, the kinetic parameters of two *CYP2D6* variants (*2D6*92* and *2D6*96*) could not be detected, due to the defect of the *CYP2D6* gene.

Conclusion: As the first report of all aforementioned alleles for dapoxetine metabolism, these data may help in the clinical assessment of the metabolic elimination of dapoxetine and may provide fundamental information for further clinical studies.

Keywords: genetic polymorphism, *CYP2D6* variants, drug metabolism, dapoxetine, personalized treatment

Introduction

Polymorphism in the cytochrome P450 (CYP) family may have the most impact on the metabolism of therapeutic drugs. *CYP2D6*, *CYP2C9*, *CYP2C19*, and *CYP3A4* polymorphisms account for the most frequent variations in Phase I metabolism of drugs, since almost 80% of drugs are metabolized by these enzymes.¹ *CYP2D6* is one of the highly polymorphic enzymes and participates in the metabolism of many therapeutic drugs that are commonly used in clinic, including the antidepressants fluoxetine, amitriptyline, and venlafaxine; the antitussive dextromethorphan; the



β -adrenergic antagonists bufuralol and metoprolol;² the opioid analgesics codeine, dihydrocodeine, and tramadol;³ the antipsychotic agent risperidone;⁴ and the selective serotonin reuptake inhibitor dapoxetine.⁵ *CYP2D6* polymorphisms can lead to no enzyme expression (poor metabolism), very low enzyme activity (intermediate metabolism), or typically associated with overexpression of a metabolic enzyme (ultrarapid metabolism).⁶ These may cause adverse effects and therapeutic failures, thus more attention should be paid to the *CYP2D6* polymorphism.

According to the National Center for Biotechnology Information website report, 370 variable sites of *CYP2D6* have been found and more than 100 *CYP2D6* alleles have been identified and named by the Human CYP Allele Nomenclature Committee (<http://www.cypalleles.ki.se/cyp2d6.htm>). In 2013, Qian et al⁷ analyzed the *CYP2D6* gene of 2,129 unrelated healthy Chinese volunteers and detected 165 mutated sites, of which 67 sites were discovered for the first time. Among these, 22 novel mutation sites were nonsynonymous, and of them 12 mutation sites were named as *87–*93, *94A, *94B, and *95–*98 by the Human CYP Allele Nomenclature Committee.⁷ In later study, 22 newly reported *CYP2D6* isoforms were transiently expressed to assess the enzymatic activity of these variants on dextromethorphan and bufuralol.^{8,9}

Premature ejaculation (PE) is a common problem, with a global prevalence estimated to be 20%–40%¹⁰ and has significant impact not only on the sufferer, but also on the partner, in terms of self-esteem, interpersonal distress, and sexual satisfaction.¹¹ Dapoxetine, a selective serotonin reuptake inhibitor,

is used for the treatment of PE in men aged 18–64 years.¹² However, dapoxetine has numerous adverse effects like nausea, diarrhea, dizziness, insomnia, and nasopharyngitis.^{13–15} In addition, dapoxetine has no pharmacokinetic interactions with food, alcohol, or phosphodiesterase type 5 (PDE5) inhibitors.^{16,17} Dapoxetine is primarily metabolized by *CYP3A4* and *CYP2D6*.⁵ Thus, the exploration of *CYP3A4* or *CYP2D6* gene polymorphisms on dapoxetine metabolism can be meaningful. In this study, we focus on the catalytic activities of 24 *CYP2D6* isoforms on dapoxetine metabolism in vitro by detecting its two metabolites generated by *CYP2D6* enzyme (shown in Figure 1). We hope these findings can provide reference for rational administration of drugs in the clinic and promote the development of personalized medicine.

Materials and methods

Chemicals and materials

Dapoxetine, desmethyldapoxetine, dapoxetine-N-oxide, and carbamazepine were obtained from Sigma-Aldrich (St Louis, MO, USA). The UPLC[®] BEH C18 column (2.1 mm \times 50 mm, 1.7 μ m) was obtained from the Waters (Ireland). Nicotinamide adenine dinucleotide phosphate was obtained from Promega (Madison, WI, USA). Formic acid (analytical reagent grade) was purchased from Sigma-Aldrich. Ultrapure water was obtained from a Milli-Q system (Millipore, Bedford, MA, USA). Liquid chromatography grade methanol and acetonitrile were purchased from Merck Chemicals Co., Ltd. (Darmstadt, Germany). Other chemicals and solvents were of analytical grade from Chemical Industries (Beijing, People's Republic of China).




Figure 1 Structures of the analytes and Phase I metabolic pathway of dapoxetine by *CYP2D6* enzyme.

Notes: (A) Dapoxetine hydrochloride. (B) Desmethyldapoxetine. (C) Dapoxetine-N-oxide.

Instrumentation

Samples were analyzed by the ultra-performance liquid chromatography tandem mass-spectrometry with ACQUITY UPLC H-Class and XEVO TQD triple-quadrupole mass spectrometer (Waters Corp., Milford, MA, USA) equipped with an electrospray ionization interface. MassLynx 4.1 software (Waters Corp.) was used to control the instrument and process all the data of the samples.

Incubation conditions

Recombinant human *CYP2D6* enzymes (the wild-type *CYP2D6*1* and 24 *CYP2D6* variants) generated in *Spodoptera frugiperda* 21 insect cells were obtained according to the previously reported method.⁸ The incubation mixture as the final assay concentration included 176.6 μL 100 mmol/L potassium phosphate buffer (pH 7.4), 5 pmol wild-type *CYP2D6*1* or other *CYP2D6* recombinant variants, 5 pmol purified cytochrome b5, and 1.71 μL of dapoxetine, which was made to the total volume of 200 μL . Dapoxetine was initially prepared in methanol solution and the concentration range was adjusted from 25 to 3,200 μM . The total concentration of methanol in the mixture was $<0.5\%$. After incubating for 5 minutes, 1 mM nicotinamide adenine dinucleotide phosphate-regenerating system (1.3 mM NADP⁺, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl₂, and 0.4 unit/mL glucose-6-phosphate dehydrogenase) was added. The mixture was incubated at 37°C for 40 minutes. In addition, the experiments were carried out in individual tubes and kept parallel, one for each concentration point. The reaction in tubes was terminated by cooling to -80°C immediately. Then 400 μL acetonitrile and 40 μL internal standard carbamazepine were added. Carbamazepine was dissolved in acetonitrile solution at a concentration of 1 $\mu\text{g}/\text{mL}$. After vortexing for 2 minutes and centrifuging at 13,000 rpm for 10 minutes in 4°C environment, the supernatant of each tube was 1:1 diluted with ultrapure water and 2 μL was injected into the ultra-performance liquid chromatography tandem mass-spectrometry system. The data were analyzed using SPSS Version 13.0 (SPSS Inc., Chicago, IL, USA). All the experimental results were as mean \pm standard deviation (SD) of three parallel measurements. All experiments were approved by the Ethics Committee of Beijing Hospital.

Chromatographic conditions

The liquid chromatographic separations were performed on an UPLC BEH C18 column (2.1 mm \times 50 mm, 1.7 μm), with an inline 0.2 mm stainless steel frit filter connected to it. The column temperature was kept at 40°C constantly, while the samples in the autosampler room were maintained at 4°C with an injection volume of 2 μL for detection. The initial mobile

phase consisted of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.4 mL/min. Elution was in a linear gradient as follow: the acetonitrile content changing from 30% to 85% between 0 and 1 minute, maintained at 85% for 1 minute, then decreased to 30% within 12 seconds. The total run time of the analytes was 3 minutes. After each injection, the sample manager underwent a needle wash process, including a strong wash (methanol-water, 50/50, v/v) and a weak wash (methanol-water, 10/90, v/v). With aforementioned appropriate conditions, the retention times of desmethyldapoxetine, dapoxetine-N-oxide, dapoxetine, and carbamazepine were at 1.40, 1.45, 1.50, and 1.23 minutes, respectively.

Mass spectrometric conditions

A Waters XEVO TQD triple-quadrupole mass spectrometer, equipped with an electrospray ionization source, was set to positive electrospray ionization in multiple reaction-monitoring mode. Nitrogen was used as the desolvation gas (600 L/h) and cone gas (50 L/h). The selected ion monitoring conditions were defined as follows: capillary voltage 2.5 kV; source temperature 150°C; and desolvation temperature 500°C. The multiple reaction-monitoring mode of transitions as quantitative analysis were m/z 306.0 \rightarrow 261.1, m/z 292.0 \rightarrow 261.1, m/z 322.0 \rightarrow 261.1, and m/z 237.0 \rightarrow 194.1 for dapoxetine, desmethyldapoxetine, dapoxetine-N-oxide, and IS, respectively. The collision energy was set at 25 V for dapoxetine, desmethyldapoxetine, and dapoxetine-N-oxide, while 20 V for carbamazepine; the cone voltage was set at 50 V for dapoxetine, desmethyldapoxetine, and dapoxetine-N-oxide, while 40 V for carbamazepine, respectively.

Statistical analysis

The kinetic parameters (K_m and V_{max}) were performed by non-linear regression curve fitting using the computer program Prism version 5 (GraphPad Software Inc., San Diego, CA, USA). One-way analysis of variance was used for intergroup comparison. Dunnett's test was used to analyze differences in catalytic activity between *CYP2D6*1* and other *CYP2D6* mutants. Kinetic data for each variant were presented as the mean \pm SD of three independent experiments. Statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA), with $P < 0.05$ considered statistically significant.

Results

From the aforementioned study, the catalytic activities of the wild-type and 24 allelic variants of *CYP2D6* were assessed, using dapoxetine as the substrate drug. Michaelis–Menten plots of the tested 25 *CYP2D6* enzymes are shown in Figures 2 and 3, and corresponding kinetic parameters are summarized in




Figure 2 Michaelis–Menten curves of the enzymatic activity of the wild-type and 24 variants toward dapoxetine demethylation (each point represents the mean ± standard deviation of three parallel experiments).

Note: The allelic variants with designated allele names have been properly arranged into six groups.

Tables 1 and 2. The intrinsic clearance (V_{max}/K_m) values of dapoxetine were significantly altered in most of the allelic variants, except occasionally a few, according to the analysis of its two metabolites. The relative clearance graph (compared with that of *2D6*1*) of dapoxetine demethylation and oxidation is shown in Figure 4.

The results of *CYP2D6* allelic variants on dapoxetine demethylation are represented in Figure 2 and Table 1. Twelve of the allelic variants exhibited obvious reduced V_{max} values when compared with *2D6*1* (count as 100%): three mutants (*2D6*10*, **93*, and *R440C*) obviously reduced to 19.77%–29.41%; nine variants (*2D6*2*, **87*,




Figure 3 Michaelis–Menten curves of the enzymatic activity of the wild-type and 24 variants toward dapoxetine oxidation (each point represents the mean \pm standard deviation of three parallel experiments).

Note: The allelic variants with designated allele names have been properly arranged into six groups.

*89, *95, *97, *98, R25Q, R344Q, and R497C) decreased to 43.64%–61.11%. Moreover, most variants showed no obvious changes on K_m values: eight variants (2D6*2, *88, *90, F164L, F219S, V327M, D336N, and V342M) showed no statistical difference; six variants (2D6*10, *87, *95,

*97, *98, and E215K) mildly decreased to 78.40%–84.22%; six variants (2D6*91, *93, *94, R25Q, R344Q, and R497C) lightly increased to 108.57%–123.40%. Except two variants (2D6*89 and R440C), their K_m values decreased to 56.58% and 62.08%, respectively. As a result, V_{max}/K_m values for

Table 1 Kinetic parameters from demethylation by recombinant wild-type and 24 *CYP2D6* allelic variants on dapoxetine

Variants	Allele frequency (%)	V _{max} (pmol/min/nmol of P450)	K _m (μM)	Intrinsic clearance (V _{max} /K _m)	Relative clearance (% of wild-type)
2D6*1	26.56	875.97±2.78	105.67±1.24	8.29±0.07	100.00
2D6*2 (R296C; S486T)	10.34	435.23±11.15 [#]	106.35±15.08	4.14±0.45 [#]	49.63
2D6*10 (P34S; S486T)	42.86	173.17±2.47 [#]	82.84±8.21 [#]	2.10±0.22 [#]	25.31
2D6*87 (A5V)	0.023	495.90±7.22 [#]	87.53±1.23 [#]	5.67±0.10 [#]	68.37
2D6*88 (V104A)	0.094	738.30±2.42 [#]	101.05±1.19	7.31±0.09 [#]	88.12
2D6*89 (L142S)	0.023	459.87±4.53 [#]	59.79±0.74 [#]	7.69±0.04	92.81
2D6*90 (K147R)	0.047	752.30±2.69 [#]	101.71±7.36	7.42±0.50 [#]	89.55
2D6*91 (C161S)	0.023	934.33±11.67 [#]	124.10±6.18 [#]	7.54±0.28 [#]	90.90
2D6*92 (218frameshift)	0.023	ND	ND	ND	ND
2D6*93 (T249P)	0.023	257.60±1.56 [#]	152.17±2.98 [#]	1.69±0.03 [#]	20.44
2D6*94 (D337G)	0.164	842.97±2.43 [#]	114.73±1.99 [#]	7.35±0.11 [#]	88.66
2D6*95 (R388H)	0.047	531.20±10.15 [#]	87.43±5.41 [#]	6.09±0.25 [#]	73.39
2D6*96 (424STOP)	0.074	ND	ND	ND	ND
2D6*97 (F457L)	0.047	462.97±4.63 [#]	77.76±8.39 [#]	6.00±0.62 [#]	72.34
2D6*98 (H463D)	0.023	497.17±5.66 [#]	78.70±4.43 [#]	6.33±0.29 [#]	76.30
R25Q	0.023	444.13±7.17 [#]	130.40±4.72 [#]	3.41±0.07 [#]	41.13
F164L	0.023	679.03±3.60 [#]	94.51±0.55	7.19±0.07 [#]	86.70
E215K	0.047	720.67±7.66 [#]	89.00±2.10 [#]	8.10±0.11	97.70
F219S	0.023	687.53±9.68 [#]	115.10±8.85	5.99±0.37 [#]	72.19
V327M	0.023	638.90±16.53 [#]	99.07±5.17	6.45±0.17 [#]	77.91
D336N	0.023	750.67±3.29 [#]	99.67±1.47	7.53±0.09 [#]	90.85
V342M	0.023	793.97±1.95 [#]	110.90±0.87	7.16±0.06 [#]	86.39
R344Q	0.023	535.30±4.49 [#]	127.67±2.15 [#]	4.19±0.04 [#]	50.58
R440C	0.023	231.77±1.36 [#]	65.5±2.59 [#]	3.54±0.13 [#]	42.64
R497C	0.023	382.27±1.40 [#]	128.00±3.12 [#]	2.98±0.08 [#]	36.06

Notes: Data are presented as the mean ± standard deviation of three parallel experiments. Significantly different from the wild-type, [#]*P*<0.05.

Abbreviation: ND, not determined.

dapoxetine demethylation were altered in majority of these allelic variants (2D6*2, *10, *87, *88, *90, *91, *93, *94, *95, *97, *98, *R25Q, F164L, F219S, V327M, D336N, V342M, R344Q, R440C, and R497C). Definitely, *CYP2D6* allelic variants could be classified into categories, according to their intrinsic clearance values when compared with the counterpart of the wild-type (counted as 100%): six variants (2D6*2, *10, *93, R25Q, R440C, and R497C) exhibited obviously decreased intrinsic clearance values (20.44%–49.63% relative clearance); 14 alleles (*CYP2D6**87, *88, *90, *91, *94, *95, *97, *98, F164L, F219S, V327M, D336N, V342M, and R344Q) exhibited slight reduction (50.58%–90.90% relative clearance). Another two variants (2D6*89 and E215K) were without distinct difference (92.81% and 97.70% relative clearance), according to the statistical analyses.

The results of the oxidative metabolism of dapoxetine are shown in Figure 3 and Table 2. Most of the tested allelic variants exhibited no significant changes on V_{max} and/or K_m values when compared with the counterparts of 2D6*1 (count as 100%). Two variants (2D6*93 and *94) exhibited

obviously increased V_{max} values (124.95%–135.58%); five variants (2D6*10, *97, R25Q, E215K, and R497C) decreased to 33.26%–80.63%. Four variants (2D6*93, *97, *98, and D336N) exhibited significantly increased K_m values with ~1.78- to 4.98-fold as compared with 2D6*1. Consequently, V_{max}/K_m values for dapoxetine oxidation were altered in most of the tested allelic variants (2D6*2, *10, *87, *88, *90, *91, *93, *94, *95, *97, *98, *R25Q, F164L, F219S, V327M, D336N, V342M, R344Q, R440C, R497C), except 2D6*90, *94, and V342M without statistical significance. Compared with the V_{max}/K_m value of 2D6*1 (count as 100%), eight variants (2D6*10, *93, *95, *97, *98, R25Q, V327M, and R497C) significantly declined to 27.56%–49.80%; eleven alleles (*CYP2D6**2, *87, *88, *89, *91, F164L, E215K, F219S, D336N, R344Q, and R440C) exhibited mild decreases (50.34%–84.64%). Three variants 2D6*90, 2D6*94, and V342M represented no significant increase (106.17%–109.98% relative clearance).

Furthermore, two defective alleles (*CYP2D6**92 and *CYP2D6**96) showed extremely low activity or no activity. Thus, the concentrations of both metabolites were below

Table 2 Kinetic parameters from oxidational activities of recombinant wild-type and 24 *CYP2D6* allelic variants toward dapoxetine

Variants	V _{max} (pmol/min/nmol of P450)	K _m (μM)	Intrinsic clearance (V _{max} /K _m)	Relative clearance (% of wild-type)
2D6*1	207.53±8.50	633.67±41.26	0.33±0.01 [#]	100.00
2D6*2 (R296C; S486T)	185.47±12.00	976.20±165.80	0.19±0.019 [#]	58.45
2D6*10 (P34S; S486T)	69.03±1.96 [#]	713.83±35.61	0.10±0.00 [#]	29.51
2D6*87 (A5V)	180.00±7.32	1,092.00±98.24	0.17±0.01 [#]	50.34
2D6*88 (V104A)	185.07±4.65	728.57±22.52	0.25±0.00 [#]	77.44
2D6*89 (L142S)	211.30±2.17	909.57±35.66	0.23±0.01 [#]	70.87
2D6*90 (K147R)	235.63±2.90	653.33±19.20	0.36±0.01	109.98
2D6*91 (C161S)	180.37±9.51	650.30±65.29	0.28±0.00 [#]	84.64
2D6*92 (218frameshift)	ND	ND	ND	ND
2D6*93 (T249P)	281.37±41.02 [#]	3,152.67±792.26 [#]	0.09±0.01 [#]	27.56
2D6*94 (D337G)	259.30±11.01 [#]	733.90±76.05	0.35±0.02	107.78
2D6*95 (R388H)	203.20±21.45	1,263.67±206.41	0.16±0.01 [#]	49.26
2D6*96 (424STOP)	ND	ND	ND	ND
2D6*97 (F457L)	162.10±7.40 [#]	1,130.73±124.75 [#]	0.14±0.01 [#]	43.90
2D6*98 (H463D)	181.03±12.67	1,462.33±102.81 [#]	0.12±0.00 [#]	37.73
R25Q	144.77±4.71 [#]	889.77±70.63	0.16±0.01 [#]	49.80
F164L	211.27±17.17	1,012.80±228.04	0.21±0.03 [#]	65.14
E215K	167.33±6.80 [#]	826.27±48.18	0.20±0.00 [#]	61.74
F219S	206.80±6.92	842.17±104.41	0.25±0.02 [#]	75.18
V327M	184.30±8.56	1,254.00±169.27	0.15±0.01 [#]	45.11
D336N	232.80±7.88	1,276.33±119.40 [#]	0.18±0.01 [#]	55.82
V342M	224.47±5.79	646.37±65.41	0.35±0.03	106.17
R344Q	187.47±11.78	935.20±143.54	0.20±0.02 [#]	61.22
R440C	191.17±7.27	829.87±86.35	0.23±0.02 [#]	70.45
R497C	115.30±4.05 [#]	995.10±75.38	0.12±0.00 [#]	35.42

Notes: Data are presented as the mean ± standard deviation of three parallel experiments. Significantly different from the wild-type, [#]*P*<0.05.

Abbreviation: ND, not determined.

the detection limit and the kinetic parameters could not be determined.

Discussion

CYP2D6 is a highly polymorphic enzyme and is involved in the metabolism of many drugs. Nowadays, it participates in the metabolism of ~30% of drugs in clinic.¹⁸

The polymorphism of *CYP2D6* significantly affects the pharmacokinetics of its substrate drugs in clinic.¹⁹ The study of *CYP2D6* polymorphism, which mainly cause drug metabolism differences and result in side effects, can provide references to the clinical research. There are significant differences among various racial and ethnic population on the frequency of *CYP2D6* polymorphism.^{20,21}




Figure 4 The catalytic activity of expressed *CYP2D6* variants toward the two metabolites of dapoxetine, when compared with the counterpart values of the wild-type 2D6*1. **Note:** [#]*P*<0.05.

In our previous study, we performed a large-scale genetic investigation by sequencing the *CYP2D6* gene in 2,129 healthy Chinese volunteers and 22 novel nonsynonymous variants were discovered and detected.⁷ This finding may greatly contribute to the development of personalized medicine for the Chinese Han population.

Dapoxetine has been recently evaluated for the treatment of PE by several countries.^{22,23} It is the only drug that has been approved for the on-demand treatment of PE.²⁴ But in the process of treatment, a variety of adverse reactions occurred, so a considerable number of patients chose to spontaneously discontinue treatment with it.¹⁴ Thus, the effects of *CYP2D6* polymorphism on dapoxetine metabolism in vitro have a great significance for the basic research and personalized treatment.

Two typical variants *CYP2D6*2* and *CYP2D6*10* were served as the positive controls for the functional analysis to ensure the reliability of this study. Recently, a study demonstrated that *CYP2D6*2* exhibited a significantly decreased V_{\max}/K_m values for both bufuralol and dextromethorphan (~40% of *CYP2D6*1*) with the baculovirus expression system.⁹ For *CYP2D6*10*, the most common allelic variant in oriental populations, several functional analyses have been conducted in various expression systems²⁵ and it has higher K_m , lower V_{\max} , and lower V_{\max}/K_m values for bufuralol, dextromethorphan, debrisoquine, atomoxetine, and nortriptyline in vitro.¹⁸ Our investigation revealed that both variants presented significantly decreased V_{\max}/K_m value on dapoxetine (approximately decreased by 50% for *CYP2D6*2* and 75% for *CYP2D6*10*); these findings were consistent with the aforementioned studies.

To better understand the effects of *CYP2D6* allelic variants on the metabolism of dapoxetine, we analyzed the 22 novel *CYP2D6* variants in detail. In particular, three isoforms, *2D6*93*, *R25Q*, and *R497C*, exhibited significant changes on V_{\max}/K_m values, indicating that the amino acids in these sites have a vital impact on the metabolism of dapoxetine. For allelic isoform *CYP2D6*93*, the V_{\max}/K_m value decreased by 70%. For the other two variants, the V_{\max}/K_m value of *R497C* decreased by ~65%, while *R25Q* decreased by more than 50%. Furthermore, two allelic isoforms (*CYP2D6*92* and *CYP2D6*96*) exhibited absent metabolic activity. *CYP2D6*93* (Thr249Pro) contains one nucleotide substitution (A>C) at position 745 in the complementary DNA (cDNA), which causes an amino acid change from Thr to Pro at position 249.⁸ The Thr-249 residue is adjacent to the residues Phe-247 and Leu-248, which are located on the border of *CYP2D6* active site cavity,²⁶ because Leu-248,

Leu-110, and Phe-112 constitute one access channel for substrate entrance. We speculate that the replacement of the hydrophilic Thr with the hydrophobic Pro at position 249 might influence the spatial structure of the adjacent egress channel and thus blocks the normal entrance of the *CYP2D6* substrate.

For the isoform *R25Q*, which exhibited significantly decreased enzymatic activity on dapoxetine, it has been deduced that Arg25 is located within the transmembrane domain and acts as a halt transfer signal; thus, changes in this site might significantly decrease the enzymatic activity in vitro.²⁷ For *R497C*, previous functional predictions revealed that this allelic isoform might deleteriously affect the *CYP2D6* protein using bioinformation tools.⁷

Similar to the previously reported variants *CYP2D6*20* (211frameshift), *CYP2D6*8* (Gly169STOP), *CYP2D6*92* (218frameshift), and *CYP2D6*96* (Gln424STOP) exhibited no enzymatic activity.¹ *CYP2D6*92* variant has a one-nucleotide deletion (nucleotide C) at site 1995 in exon 4 and causes a frameshift effect: a disrupted reading frame and the premature termination of protein synthesis during its translation. *CYP2D6*96* has a single-nucleotide mutation in exon 8 C>T at position 3895 in the DNA (site 1270 in cDNA) and causes the codon 424 changing from CAG to one stop codon TAG. For *CYP2D6*92* and *CYP2D6*96*, immunoblotting results revealed that both variants were expressed as truncated proteins, which caused the functional loss of enzymatic activity.⁸ We speculate that responsibility for the deficiency of enzymatic function might be the frameshift and resulting premature termination.

Particularly, the V_{\max}/K_m values of *CYP2D6*89* and *E215K* exhibited no difference compared with *2D6*1* for demethylation, with 92.81% and 97.70%, respectively. This phenomenon is not consistent with the previous research results.

For *CYP2D6*89* (*L142S*), it contains one T to C substitution in site 1678 of the DNA sequence (425T>C in the cDNA) and results in one amino acid change from Leu to Ser at position 142.⁷ On the other hand, for *E215K*, Rowland et al²⁶ found that many important amino acid residues were essential to the active site cavity. The Glu216 residue, which is located in the F helix, plays an important role in substrate recognition and binding.²⁸ In the tested variants, *E215K* and *F219S* were located in the F helix.⁷ Dai et al⁸ indicated that *CYP2D6*89* and *E215K* exhibited >90% decrease in catalytic activity on bufuralol and dextromethorphan compared with the wild-type *CYP2D6*1*.⁸ Cai et al⁹ reported that *CYP2D6*89* decreased the metabolism of bufuralol, but had

no effect on the metabolism of dextromethorphan in vitro; E215K exhibited >97% decrease in catalytic activity on bufuralol and dextromethorphan.

As per our speculation, the different specificities of the substrate drug may be the main reason for this inconsistency. In another point of view, probing drugs cannot rule out some special factors in the process of metabolism of other drugs by one or two allelic variants.

In summary, we screened the enzymatic activity of the 24 variants of CYP2D6 on the metabolism of dapoxetine in vitro, especially the 22 novel isoforms. As the first report of all aforementioned alleles on dapoxetine metabolism, the research provided new information about CYP2D6 genetic polymorphism and related impact on its substrate drug dapoxetine; on the other hand, this study could help clinical assessment of the metabolic effects on dapoxetine, provide fundamental information to guide rational drug usage, and promote personalized medicine.

Acknowledgments

This work was supported by the Ministry of Health of the People's Republic of China (201302008), the First Affiliated Hospital of Wenzhou Medical University (FHY2015010), and a grant from the National Natural Science Foundation of China (No 31371280).

Disclosure

The authors report no conflicts of interest in this work.

References

- Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. *Drug Metab Rev.* 2009;41(2): 89–295.
- Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amphetamines, opioid analgesics and antidepressants. *Clin Toxicol (Phila).* 2015;53(6):501–510.
- Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006;30(7):1356–1358.
- Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. *Biochem Pharmacol.* 2015;93(1):104–109.
- Dapoxetine. Premature ejaculation: not worth the risk. *Prescribe Int.* 2010;19(105):12–14.
- Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. *Pharmacogenomics J.* 2006; 6(5):343–350.
- Qian JC, Xu XM, Hu GX, et al. Genetic variations of human CYP2D6 in the Chinese Han population. *Pharmacogenomics.* 2013;14(14): 1731–1743.
- Dai DP, Geng PW, Wang SH, et al. In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. *Basic Clin Pharmacol Toxicol.* 2015;117(1):39–43.
- Cai J, Dai DP, Geng PW, et al. Effects of 22 novel CYP2D6 variants found in the Chinese population on the bufuralol and dextromethorphan metabolisms in vitro. *Basic Clin Pharmacol Toxicol.* Epub 2015 Aug 27.
- McCarty E, Dinsmore W. Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation. *Core Evid.* 2012; 7:1–14.
- Owen RT. Dapoxetine: a novel treatment for premature ejaculation. *Drugs Today (Barc).* 2009;45(9):669–678.
- Jannini EA, Isidori AM, Aversa A, Lenzi A, Althof SE. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. *J Sex Med.* 2013;10(10):2359–2369.
- Yue FG, Dong L, Hu TT, Qu XY. Efficacy of dapoxetine for the treatment of premature ejaculation: a meta-analysis of randomized clinical trials on intravaginal ejaculatory latency time, patient-reported outcomes, and adverse events. *Urology.* 2015;85(4):856–861.
- Jern P, Johansson A, Piha J, Westberg L, Santtila P. Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting. *Int J Impot Res.* 2015;27(2):75–80.
- Andrews PW, Thomson JA Jr, Amstadter A, Neale MC. Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. *Front Psychol.* 2012;3:117.
- Kendirci M, Salem E, Hellstrom WJ. Dapoxetine, a novel selective serotonin transporter inhibitor for the treatment of premature ejaculation. *Ther Clin Risk Manag.* 2007;3(2):277–289.
- Modi NB, Dresser M, Desai D, Edgar C, Wesnes K. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. *J Clin Pharmacol.* 2007;47(3):315–322.
- Shen H, He MM, Liu H, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. *Drug Metab Dispos.* 2007;35(8):1292–1300.
- Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J.* 2005;5(1):6–13.
- Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. Cytochrome p450 enzyme polymorphism frequency in indigenous and native American populations: a systematic review. *Community Genet.* 2008;11(3): 141–149.
- Weber WW. Populations and genetic polymorphisms. *Mol Diagn.* 1999;4(4):299–307.
- Gur S, Sikka SC. The characterization, current medications, and promising therapeutics targets for premature ejaculation. *Andrology.* 2015; 3(3):424–442.
- Giuliano F, Clement P. Pharmacology for the treatment of premature ejaculation. *Pharmacol Rev.* 2012;64(3):621–644.
- Cormio L, Massenio P, La Rocca R, Verze P, Miron V, Carrieri G. The Combination of dapoxetine and behavioral treatment provides better results than dapoxetine alone in the management of patients with lifelong premature ejaculation. *J Sex Med.* 2015;12(7):1609–1615.
- Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. *Drug Metab Pharmacokinet.* 2012;27(1):68–84.
- Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6. *J Biol Chem.* 2006;281(11):7614–7622.
- Sakuyama K, Sasaki T, Ujiie S, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57). *Drug Metab Dispos.* 2008;36(12):2460–2467.
- Guengerich FP, Hanna IH, Martin MV, Gillam EM. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. *Biochemistry.* 2003;42(5):1245–1253.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>